A 42-year-old woman with a 6-month history of progressive fatigue, weight gain, and cold intolerance presents with a painless, firm, diffusely enlarged thyroid. TSH is 8.2 mIU/L, free T4 is 9 pmol/L (low-normal), TPO antibodies are positive (>500 IU/mL), and thyroglobulin antibodies are positive. Ultrasound shows heterogeneous echotexture with multiple hypoechoic nodules. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Chronic Autoimmune Thyroiditis (Hashimoto's Thyroiditis) ### Key Clinical Features **Key Point:** Positive TPO and thyroglobulin antibodies in a patient with hypothyroid symptoms (fatigue, weight gain, cold intolerance), elevated TSH, and low-normal free T4 confirm chronic autoimmune thyroiditis (Hashimoto's disease). **High-Yield:** Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions and is characterized by: - Gradual onset of hypothyroid symptoms - Elevated TSH with low or low-normal free T4 - Positive TPO and thyroglobulin antibodies (>95% sensitivity for diagnosis) - Firm, diffusely enlarged thyroid (goiter) - Heterogeneous ultrasound echotexture (lymphocytic infiltration) - Hypoechoic nodules are common and usually benign (lymphoid aggregates) ### Management Algorithm ```mermaid flowchart TD A[Chronic autoimmune thyroiditis confirmed]:::outcome --> B{TSH level & symptoms?}:::decision B -->|TSH elevated, symptomatic| C[Start levothyroxine replacement]:::action B -->|TSH normal, asymptomatic| D[Observation, repeat TSH annually]:::action C --> E[Start low dose: 25-50 mcg daily]:::action E --> F[Recheck TSH after 6-8 weeks]:::action F --> G{TSH normalized?}:::decision G -->|No| H[Increase by 25 mcg, recheck in 6-8 weeks]:::action G -->|Yes| I[Maintenance therapy, annual monitoring]:::action B -->|Nodules present| J{Suspicious features on ultrasound?}:::decision J -->|No| K[No FNAC needed, routine follow-up]:::action J -->|Yes| L[FNAC for cytology]:::action ``` ### Why Levothyroxine Replacement is Correct 1. **Indication:** TSH is elevated (8.2 mIU/L, normal <4.5) and free T4 is low-normal (9 pmol/L, normal 10–20). The patient is symptomatic (fatigue, weight gain, cold intolerance). This meets criteria for overt hypothyroidism requiring treatment. 2. **Starting dose:** 25 mcg daily is appropriate for most patients; some guidelines recommend 50 mcg for younger, non-cardiac patients. Dose is titrated upward every 6–8 weeks based on TSH response. 3. **Target:** TSH should be normalized to 0.5–2.5 mIU/L (or patient-specific target). 4. **Monitoring:** TSH and free T4 rechecked 6–8 weeks after each dose adjustment until stable, then annually. **Clinical Pearl:** Hypoechoic nodules in Hashimoto's thyroiditis are usually benign (lymphoid aggregates, not true nodules). FNAC is NOT indicated unless nodules have suspicious ultrasound features (irregular margins, hypoechogenicity, increased vascularity, microcalcifications) or grow on follow-up. In this case, no suspicious features are mentioned. **High-Yield:** The presence of positive TPO and thyroglobulin antibodies is diagnostic of autoimmune thyroiditis. Ultrasound findings (heterogeneous echotexture, hypoechoic areas) support the diagnosis but are not required for diagnosis. Nodules in Hashimoto's are common and benign unless they meet criteria for FNAC. ### Why Other Options Are Wrong | Option | Why Incorrect | |--------|---------------| | FNAC of largest hypoechoic nodule | Hypoechoic nodules in Hashimoto's thyroiditis are usually benign lymphoid aggregates, not true nodules. FNAC is indicated only if nodules have suspicious ultrasound features (irregular margins, marked hypoechogenicity, microcalcifications, increased vascularity) or grow on follow-up. Routine FNAC of all nodules in Hashimoto's is unnecessary and increases cost and anxiety. | | Prednisolone 30 mg daily | Corticosteroids are NOT indicated in chronic autoimmune thyroiditis. They are used only in acute painful thyroiditis (de Quervain's) or severe thyroid eye disease (Graves' ophthalmopathy). Chronic Hashimoto's is managed with levothyroxine replacement, not immunosuppression. | | Thyroidectomy due to lymphoma risk | While Hashimoto's thyroiditis increases the risk of primary thyroid lymphoma (MALT lymphoma) 40–80-fold, the absolute risk is still <1%. Thyroidectomy is NOT indicated as a preventive measure. Surgery is reserved for severe goiter causing compressive symptoms or if lymphoma is confirmed on biopsy. | **Mnemonic: HASHIMOTO'S MANAGEMENT = LEVOTHYROXINE (LT4) + MONITORING** - **L**evothyroxine replacement (start low, titrate up) - **T**arget TSH normalization - **4** = TSH checked every 6–8 weeks until stable, then annually **High-Yield:** Levothyroxine is the standard of care for hypothyroidism. Combination therapy (levothyroxine + liothyronine) is not recommended by major guidelines for routine Hashimoto's. Selenium supplementation and iodine avoidance may be considered in some cases but are not standard first-line management. [cite:Harrison 21e Ch 405; Robbins 10e Ch 24]